ArticleInvestigational new drugs2014

Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.

Yoshito Komatsu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.